NCCN Category 1 Recommendation3*

Liposomal irinotecan (ONIVYDE®) + 5-FU/LV is the only Category 1 NCCN chemotherapy recommendation for patients with post-gemcitabine metastatic pancreatic cancer with good performance status and disease progression3†

Tumor typeLine of therapyNCCN recommendationNCCN Category
Metastatic pancreatic cancerSecond-line, with previous gemcitabine-based therapy5-FU/LV + liposomal irinotecan for patients with metastatic pancreatic cancer who have a good performance status1

*Therapies are categorized based on National Comprehensive Cancer Network (NCCN) categories of evidence and consensus, which are defined as follows: 1: Based upon high-level evidence, there is uniform NCCN consensus that the intervention is appropriate; 2A: Based upon lower-level evidence, there is uniform NCCN consensus that the intervention is appropriate; 2B: Based upon lower-level evidence, there is NCCN consensus that the intervention is appropriate. All recommendations are category 2A unless otherwise noted.3

Good performance status is defined as ECOG 0-1, with good biliary drainage and adequate nutritional intake.3

NCCN makes no warranties of any kind whatsoever regarding their content, use, or application and disclaims any responsibility for their application or use in any way.

5-FU=fluorouracil; ECOG=Eastern Cooperative Oncology Group; LV=leucovorin.

Tumor type
Metastatic pancreatic cancer
Line of therapy
Second-line, with previous gemcitabine-based therapy
NCCN recommendation
5-FU/LV + liposomal irinotecan for patients with metastatic pancreatic cancer who have a good performance status
NCCN Category
1

*Therapies are categorized based on National Comprehensive Cancer Network (NCCN) categories of evidence and consensus, which are defined as follows: 1: Based upon high-level evidence, there is uniform NCCN consensus that the intervention is appropriate; 2A: Based upon lower-level evidence, there is uniform NCCN consensus that the intervention is appropriate; 2B: Based upon lower-level evidence, there is NCCN consensus that the intervention is appropriate. All recommendations are category 2A unless otherwise noted.3

Good performance status is defined as ECOG 0-1, with good biliary drainage and adequate nutritional intake.3

NCCN makes no warranties of any kind whatsoever regarding their content, use, or application and disclaims any responsibility for their application or use in any way.

5-FU=fluorouracil; ECOG=Eastern Cooperative Oncology Group; LV=leucovorin.